Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial
/in HIV/AIDS, International Publications /von 2006-06-01 / J. Med. Virol. 2006 Jun;78(6):711-8Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients
/in Hypernephroma, International Publications /von 2006-06-01 / Cancer Res. 2006 Jun;66(11):5910-8Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial
/in International Publications, Prostate Cancer /von 2006-06-01 / Prostate 2006 Jun;66(8):811-21HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination
/in Breast Cancer, Dendritic Cells, International Publications /von 2006-05-25 / Gene Ther. 2006 Oct;13(19):1391-402Analysis of cell proliferation and cell death during in situ hyperthermic treatment of neoplastic cells: a case report of human non-Hodgkin lymphoma
/in Hyperthermia, International Publications, Malignant Lymphoma /von 2006-05-24 / Biomed. Pharmacother. 2006 Jun;60(5):227-32Induction of primary human T cell responses against hepatitis C virus-derived antigens NS3 or core by autologous dendritic cells expressing hepatitis C virus antigens: potential for vaccine and immunotherapy
/in Chronic Virus Hepatitis, International Publications /von 2006-05-15 / J. Immunol. 2006 May;176(10):6065-75Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients
/in International Publications, Malignant Melanoma /von 2006-05-15 / Int. J. Cancer 2006 May;118(10):2617-27Virology- and immunology-based gene therapy for cancer
/in Dendritic Cells, International Publications /von 2006-05-12 / Cancer Immunol. Immunother. 2006 Nov;55(11):1420-5Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA
/in International Publications, Malignant Melanoma /von 2006-05-05 / Cancer Gene Ther. 2006 Oct;13(10):905-18
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de